3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Leukemia, Myeloid, Acute
47
Precursor Cell Lymphoblastic Leukemia-Lymphoma
32
Myelodysplastic Syndromes
27
Multiple Myeloma
20
Recurrence
19
Lymphoma, Non-Hodgkin
15
Lymphoma, B-Cell
14
Lymphoma
14
Leukemia, Lymphocytic, Chronic, B-Cell
13
Ovarian Neoplasms
12
Hematologic Neoplasms
12
Melanoma
11
Pancreatic Neoplasms
10
Myeloproliferative Disorders
10
Burkitt Lymphoma
10
Leukemia
9
Hodgkin Disease
9
Stomach Neoplasms
8
Lymphoma, Large B-Cell, Diffuse
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Leukemia, Biphenotypic, Acute
8
Neoplasms
7
Leukemia, Myelomonocytic, Chronic
7
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
6
Osteosarcoma
6
Neuroblastoma
6
Neoplasm Metastasis
6
Lymphoma, Mantle-Cell
6
Lymphoma, Follicular
6
Interventions
Magnetic Resonance Spectroscopy
5
Cyclophosphamide
5
dinutuximab
3
Topotecan
3
Etoposide
3
Doxorubicin
3
Carboplatin
3
Biopsy
3
sargramostim
2
Vincristine
2
Thiotepa
2
Stem Cell Transplantation
2
Specimen Handling
2
Radiation
2
Platinum
2
Melphalan
2
Isotretinoin
2
Colony-Stimulating Factors
2
Cisplatin
2
1,2-diaminocyclohexaneplatinum II citrate
2
iberdomide
1
gallium Ga 68 dotatate
1
fludarabine
1
Watchful Waiting
1
Transurethral Resection of Bladder
1
Temozolomide
1
Razoxane
1
Radiotherapy
1
Proton Therapy
1
Observation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ganglioneuroblastoma
×
fludarabine
×
90 days
×
Clear all
NCT07502287
2026-03-30
DUAL-NK-NB
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled